News

Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
HAYA Therapeutics wins FDA Fast Track designation for HTX-001 in heart disease
read more
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
Amorphical completes Phase 2 enrolment for AMOR-1 in hypoparathyroidism
read more
Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
Claris Bio raises $118 million to advance potential first drug treatment for LSCD
read more
Drug Delivery & Formulation,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development
ProBioGen and VarmX partner on second Factor X candidate
read more
Medical devices,Research & Development
Quantum-enhanced MRI project targets higher-resolution brain metastases imaging
read more
Biotech & Pharma Business,Manufacturing & Supply Chain,Research & Development,Uncategorised
China biotech growth faces US policy scrutiny despite scientific progress
read more
Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Research & Development
FDA allows Medicus Pharma to start SkinJect study in patients with Gorlin Syndrome
read more
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
ViiV Healthcare HIV regimen Dovato non-inferior to Biktarvy in Phase 3b study
read more
Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Research & Development
Seegene data finds STI pathogens in 82% of HPV-positive test results
read more
Digital & Data,Drug Delivery & Formulation,Research & Development
AI-driven antibody discovery could create $7bn market for life science tools
read more
Clinical & Regulatory,Manufacturing & Supply Chain
Pace Life Sciences passes FDA inspection at North Carolina facility
read more
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
CAMP4 wins Australian clearance to begin Phase 1/2 trial of SYNGAP1 therapy
read more
Genomics and sequencing,Research & Development
Novogene expands single-cell sequencing capability in Cambridge
read more
Manufacturing & Supply Chain,Medical devices,Research & Development
Femtosecond lasers could offer alternative to PFAS coatings
read more
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
CHMP recommends EU marketing authorisation for two obicetrapib treatments
read more
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
CHMP recommends EU approval of Lynavoy for cholestatic pruritus in PBC
read more

HAYA Therapeutics wins FDA Fast Track designation for HTX-001 in heart disease

Amorphical completes Phase 2 enrolment for AMOR-1 in hypoparathyroidism

Claris Bio raises $118 million to advance potential first drug treatment for LSCD

ProBioGen and VarmX partner on second Factor X candidate

Quantum-enhanced MRI project targets higher-resolution brain metastases imaging

China biotech growth faces US policy scrutiny despite scientific progress

FDA allows Medicus Pharma to start SkinJect study in patients with Gorlin Syndrome

ViiV Healthcare HIV regimen Dovato non-inferior to Biktarvy in Phase 3b study

Seegene data finds STI pathogens in 82% of HPV-positive test results

AI-driven antibody discovery could create $7bn market for life science tools

Pace Life Sciences passes FDA inspection at North Carolina facility

CAMP4 wins Australian clearance to begin Phase 1/2 trial of SYNGAP1 therapy

Novogene expands single-cell sequencing capability in Cambridge

Femtosecond lasers could offer alternative to PFAS coatings

CHMP recommends EU marketing authorisation for two obicetrapib treatments

CHMP recommends EU approval of Lynavoy for cholestatic pruritus in PBC

main menu

recent posts

Qureight expands London operations to develop AI chest imaging model

Limbic selected for FDA pilot to test AI-led mental healthcare

APAC ablation catheter market set to grow 14% as pulsed field ablation gains ground

get connected